The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain

Neuropharmacology

Volumn 53, Issue 1, 2007, Pages 169-177

  Liang, Ying Ching ^a   Huang, Chiung Chun ^a   Hsu, Kuei Sen ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Allodynia; Cannabinoids; CB1 receptor; Chronic constriction injury (CCI); Hyperalgesia; Trigeminal neuropathic pain

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CAPSAZEPINE; DEXANABINOL; VANILLOID RECEPTOR 1;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; HEATING; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; MALE; MECHANICAL STIMULATION; NERVE COMPRESSION; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; ROTAROD TEST; THERMAL STIMULATION; TRIGEMINAL NERVE; TRIGEMINAL NUCLEUS; TRIGEMINUS NEURALGIA; VIBRISSA; WESTERN BLOTTING;

ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; BENZOXAZINES; CANNABINOIDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FUNCTIONAL LATERALITY; HYPERALGESIA; HYPERESTHESIA; INDOLES; MALE; MORPHOLINES; NAPHTHALENES; PAIN MEASUREMENT; PAIN THRESHOLD; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTOR, CANNABINOID, CB1; TIME FACTORS; TRIGEMINAL NERVE DISEASES;

EID: 34547189814     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.04.019     Document Type: Article

References (41)

1. Ameri A. The effects of cannabinoids on the brain. Prog. Neurobiol. 58 (1999) 315-348
2. Bennett G.J., and Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107
3. Costa B., Siniscalco D., Trovato A.E., Comelli F., Sotgiu M.L., Colleoni M., Maione S., Rossi F., and Giagnoni G. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br. J. Pharmacol. 148 (2006) 1022-1032
4. Elmes S.J., Winyard L.A., Medhurst S.J., Clayton N.M., Wilson A.W., Kendall D.A., and Chapman V. Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 118 (2005) 327-335
5. Felder C.C., and Glass M. Cannabinoid receptors and their endogenous agonists. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 179-200
6. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., and James I. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92 (2001) 91-100
7. Fromm G.H. Trigeminal neuralgia and related disorders. Neurol. Clin. 7 (1989) 305-319
8. Glass M., Dragunow M., and Faull R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77 (1997) 299-318
9. Herzberg U., Eliav E., Bennett G.J., and Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 221 (1997) 157-160
10. Ibrahim M.M., Porreca F., Lai J., Albrecht P.J., Rice F.L., Khodorova A., Davar G., Makriyannis A., Vanderah T.W., Mata H.P., and Malan Jr. T.P. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3093-3098
11. Ibrahim M.M., Rude M.L., Stagg N.J., Mata H.P., Lai J., Vanderah T.W., Porreca F., Buckley N.E., Makriyannis A., and Malan Jr. T.P. CB2 cannabinoid receptor mediation of antinociception. Pain 122 (2006) 36-42
12. Imamura Y., and Kawamoto H. An Immunohistochemical Study of Trigeminal Mononeuropathy in Rats. Abstract of the 7th World Congress on Pain (1993) 39
13. Imamura Y., Kawamoto H., and Nakanishi O. Characterization of heat-hyperalgesia in an experimental trigeminal neuropathy in rats. Exp. Brain Res. 116 (1997) 97-103
14. Li J., Daughters R.S., Bullis C., Bengiamin R., Stucky M.W., Brennan J., and Simone D.A. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain 81 (1999) 25-33
15. Liang Y.C., Huang C.C., and Hsu K.S. Therapeutic potential of cannabinoids in trigeminal neuralgia. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 507-514
16. Liang Y.C., Huang C.C., Hsu K.S., and Takahashi T. Cannabinoid-induced presynaptic inhibition at the primary afferent trigeminal synapse of juvenile rat brainstem slices. J. Physiol. 555 (2004) 85-96
17. Lichtman A.H., and Martin B.R. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258 (1991) 517-523
18. Lim G., Sung B., Ji R.R., and Mao J. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105 (2003) 275-283
19. Liu P., Bilkey D.K., Darlington C.L., and Smith P.F. Cannabinoid CB1 receptor protein expression in the rat hippocampus and entorhinal, perirhinal, postrhinal and temporal cortices: regional variations and age-related changes. Brain Res. 979 (2003) 235-239
20. Love S., and Coakham H.B. Trigeminal neuralgia: pathology and pathogenesis. Brain 124 (2001) 2347-2360
21. Malan Jr. T.P., Ibrahim M.M., Vanderah T.W., Makriyannis A., and Porreca F. Inhibition of pain responses by activation of CB2 cannabinoid receptors. Chem. Phys. Lipids 121 (2002) 191-200
22. Martin W.J., Loo C.M., and Basbaum A.I. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 82 (1999) 199-205
23. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
24. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
25. Nomura H., Ogawa A., Tashiro A., Morimoto T., Hu J.W., and Iwata K. Induction of Fos protein-like immunoreactivity in the trigeminal spinal nucleus caudalis and upper cervical cord following noxious and non-noxious mechanical stimulation of the whisker pad of the rat with an inferior alveolar nerve transection. Pain 95 (2002) 225-238
26. Palazzo E., Marabese I., de Novellis V., Oliva P., Rossi F., Berrino L., Rossi F., and Maione S. Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology 40 (2001) 319-326
27. Pascual D., Goicoechea C., Suardiaz M., and Martin M.I. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 118 (2005) 23-34
28. Patwardhan A.M., Jeske N.A., Price T.J., Gamper N., Akopian A.N., and Hargreaves K.M. The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 11393-11398
29. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 63 (2001) 569-611
30. Price T.J., Helesic G., Parghi D., Hargreaves K.M., and Flores C.M. The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat. Neuroscience 120 (2003) 155-162
31. Price T.J., Patwardhan A., Akopian A.N., Hargreaves K.M., and Flores C.M. Cannabinoid receptor-independent actions of the aminoalkylindole WIN 55,212-2 on trigeminal sensory neurons. Br. J. Pharmacol. 142 (2004) 257-266
32. Rappaport Z.H., and Devor M. Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. Pain 56 (1994) 127-318
33. Sagar D.R., Kelly S., Millns P.J., O'Shaughnessey C.T., Kendall D.A., and Chapman V. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur. J. Neurosci. 22 (2005) 371-379
34. Siegling A., Hofmann H.A., Denzer D., Mauler F., and De Vry J. Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain. Eur. J. Pharmacol. 415 (2001) R5-R7
35. Smith F.L., Fujimori K., Lowe J., and Welch S.P. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol. Biochem. Behav. 60 (1998) 183-191
36. Vos B.P., Strassman A.M., and Maciewicz R.J. Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat's infraorbital nerve. J. Neurosci. 14 (1994) 2708-2723
37. Vos B.P., Benoist J.M., Gautron M., and Guilbaud G. Changes in neuronal activities in the two ventral posterior medial thalamic nuclei in an experimental model of trigeminal pain in the rat by constriction of one infraorbital nerve. Somatosens. Mot. Res. 17 (2000) 109-122
38. Welch S.P., Huffman J.W., and Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J. Pharmacol. Exp. Ther. 286 (1998) 1301-1308
39. Zakrzewska J.M., and Patsalos P.N. Drugs used in the management of trigeminal neuralgia. Oral Surg. Oral Med. Oral Pathol. 74 (1992) 439-450
40. Zhang X., Bao L., Shi T.J., Ju G., Elde R., and Hokfelt T. Down-regulation of mu-opioid receptors in rat and monkey dorsal root ganglion neurons and spinal cord after peripheral axotomy. Neuroscience 82 (1998) 223-240
41. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., Julius D., and Hogestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (1999) 452-457